Team:HKUST-Hong Kong/Design Module

From 2012.igem.org

(Difference between revisions)
Line 363: Line 363:
               <h1><p align=center>Target Binding Module</p></h1>
               <h1><p align=center>Target Binding Module</p></h1>
           </div>
           </div>
-
           <p>Our decision to pursue colorectal carcinoma suppression arose from two key points obtained from preliminary research: 1) bone morphogenetic protein 2 (BMP-2) suppresses the growth of colon cancer cell growth <i>in vivo</i>, and 2) the phage display peptide RPMrel confers specific and preferential binding to non-differentiated colon cancer cells......<a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Target_binding">Click to see more</a></p>
+
           <p>Our decision to pursue colorectal carcinoma suppression arose from two key points obtained from preliminary research: 1) bone morphogenetic protein 2 (BMP2) suppresses the growth of colon cancer cell growth <i>in vivo</i>, and 2) the phage display peptide RPMrel confers specific and preferential binding to non-differentiated colon cancer cells......<a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Target_binding">Click to see more</a></p>
           </div>
           </div>
           <div id="paragraph2" class="bodyParagraphs">
           <div id="paragraph2" class="bodyParagraphs">

Revision as of 13:49, 26 September 2012

Team:HKUST-Hong Kong - 2012.igem.org

Design - Module

Target Binding Module

Our decision to pursue colorectal carcinoma suppression arose from two key points obtained from preliminary research: 1) bone morphogenetic protein 2 (BMP2) suppresses the growth of colon cancer cell growth in vivo, and 2) the phage display peptide RPMrel confers specific and preferential binding to non-differentiated colon cancer cells......Click to see more

Anti-tumor Molecule Secretion Module

As our team objective is to provide a specific and efficient drug for Colon cancer, the way of drug synthesis and releasing is a significant part of our whole project. Hence this module is focusing on the production and delivery of anti-tumor drug......click to see more

Regulation and Control Module

Our module aims at regulating the growth of our engineered bacteria B. hercules and the production of the anti-tumor drug, BMP2. We first introduce a xylose inducible promoter, which can help us control the timing of BMP-2 expression and secretion. Our choice of xylose as an inducer stems from its induction efficiency, its little existence and low absorption rate in colon......click here to see more